Biosciences
Our researchers in have a rich legacy of collaboration with government agencies and industry partners that improve health outcomes and well-being around the world. SRI Biosciences projects range from high-impact, early-stage research to drug co-development with pharmaceutical and biotech companies.
-
How the COVID-19 pandemic and machine learning delivered insights into adolescent mental health
An ABCD Study® paper delivers insights into the pandemic’s impact on adolescents.
-
SRI International announces collaboration agreement with Janssen
Collaboration focuses on SRI’s Synfini artificial intelligence and automation platform to accelerate small-molecule drug discovery.
-
SRI Bioscience awarded $14.7 million contract to continue development of high-concentration Naloxone formulation
SRI Biosciences has been awarded a contract sponsored by the Defense Threat Reduction Agency (DTRA) to continue development of a high-concentration naloxone product.
-
Formulating a solution to mass radiation exposure
In the event of a radiation leak or nuclear accident, oral medication options are needed for quick-turnaround, effective, large-scale treatment.
-
Automating chemical drug discovery and synthesis
SRI International’s continuous flow SynFini™ Suite produced multiple nucleoside antivirals in a single day.
-
Intracellular delivery—now a reality for many types of therapeutics
Unlocking the therapeutic potential of antisense oglionucleotides and other biologics.
-
Making Distributed Teams More Connected
AI-powered discussion highlights to share knowledge with remote team members.
-
Partnering to Rapidly Advance ZMappTM for Ebola Treatment
SRI scientists partner with Mapp Biopharmaceutical to accelerate FDA approval for clinical trials.
-
HOPO: Partnering to Advance Therapy for Radiation Exposure
SRI scientists collaborate with Lawrence Berkeley National Laboratory to chart a path for obtaining regulatory approval for a clinical development plan for a novel decorporation agent.
-
EcoCyc: Encyclopedia of E. coli genes and metabolism
A bioinformatics database that describes the genome, metabolic network and regulatory network of Escherichia coli.
-
BioCyc database collection
A comprehensive website for sharing fundamental information about biochemical pathways and genomes with researchers around the world
-
Techneins™ – Non-natural polymers as synthetic affinity reagents and novel therapeutics
SRI Biosciences has developed a molecular discovery platform that enables the synthesis and screening of sequence-defined non-natural polymers, or “Techneins™”, to create potent and selective affinity reagents that can be used as either therapeutics or diagnostic reagents.